• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA clears tablet-based ultrasound imaging system

Article

The FDA has granted 510(k) clearance to Escalon Medical Corp.’s tablet-based ultrasound imaging system, the Sonomed Escalon VuPad.

 

Ardmore, PA-The FDA has granted 510(k) clearance to Escalon Medical Corp.’s tablet-based ultrasound imaging system, the Sonomed Escalon VuPad.

The device-which utilizes touch screen controls-combines Sonomed Escalon’s UBM and newly enhanced B-scan image quality with an ultra-high-resolution screen that has a 25% larger viewing area than other portable devices, according to the company. Proprietary enhanced focus rendering enables the device to capture both still images and high-resolution video clips that can be reviewed frame by frame.

“The new (imaging system) is a revolutionary portable ultrasound device that delivers exceptional image quality in a wide range of ophthalmic applications,” said Richard J. DePiano Jr., chief executive officer of Escalon Medical.

The device will be on display at the annual symposium and congress of the American Society of Cataract and Refractive Surgery in Boston April 25 through April 29.

 

The company said it is anticipating CE marking and clearance by other international regulatory bodies in the coming months.

“We are pleased by the initial indications and the long-term opportunity surrounding (the device) . . . however, we may experience sales fluctuations as we update our product offering,” added DePiano. “In addition, planned increases to research and development expenses, as well as increased sales and marketing costs could pressure financial results.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.